Shares of Kodiak Sciences Inc. (NASDAQ:KOD – Get Free Report) have earned a consensus recommendation of “Reduce” from the five analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $7.00.
KOD has been the topic of a number of recent research reports. Chardan Capital lowered Kodiak Sciences from a “buy” rating to a “neutral” rating in a report on Tuesday, July 25th. UBS Group lowered Kodiak Sciences from a “buy” rating to a “neutral” rating and dropped their target price for the company from $15.00 to $4.00 in a report on Thursday, July 27th. Capital One Financial raised Kodiak Sciences from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $7.00 to $12.00 in a report on Friday. Jefferies Financial Group lowered Kodiak Sciences from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Finally, JPMorgan Chase & Co. cut Kodiak Sciences from a “neutral” rating to an “underweight” rating in a research report on Monday, July 24th.
Institutional Inflows and Outflows
Kodiak Sciences Trading Down 5.0 %
NASDAQ:KOD opened at $1.92 on Friday. The firm has a market cap of $100.74 million, a P/E ratio of -0.37 and a beta of 1.79. The stock’s 50 day simple moving average is $1.84 and its 200-day simple moving average is $4.11. Kodiak Sciences has a 12-month low of $1.37 and a 12-month high of $9.80.
Kodiak Sciences (NASDAQ:KOD – Get Free Report) last released its earnings results on Monday, August 14th. The company reported ($1.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.30). Research analysts forecast that Kodiak Sciences will post -5.2 EPS for the current fiscal year.
Kodiak Sciences Company Profile
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
- Five stocks we like better than Kodiak Sciences
- What is the Euro STOXX 50 Index?
- Williams-Sonoma is a steal for buy-and-hold investors
- How to Invest in Toy Stocks
- A closer look at Warren Buffett’s latest surprise purchase
- Insider Trades May Not Tell You What You Think
- GE stock surges to six-year high: What’s behind the move?
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.